Respiratory
Respiratory
Boehringer Ingelheim
has over 90 years
of heritage
in managing
respiratory diseases
Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life
GOLD Update 2019 Guidelines
Document ID: PC-TH-100387
01/03/2019
Author: Prof. Claus F. Vogelmeier
The new GOLD 2019 report has changed the way patients are assessed to allow for a more tailored approach in managing patients with COPD. Symptom burden and exacerbation history are the only drivers for pharmacologic therapy recommendations.
Related content
PC-TH-100292
Production date: Mar 2019
Production date: Mar 2019